Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850739 | 0.86 | GSK3B (0.47) | KDM4EMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL11277508 | 0.79 | KDM4E (0.58) | HTTCYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL4858963 | 0.77 | ALDH1A1 (0.45) | KDM4EALDH1A1FAAHL3MBTL1 | |
| SCHEMBL4856384 | 0.76 | KAT2B (0.45) | HTTCYP1A2KDM4EMEN1KMT2A | |
| SCHEMBL4859153 | 0.76 | GSK3B (0.51) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4850527 | 0.76 | GSK3B (0.51) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL14263926 | 0.75 | LMNA (0.43) | HTTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL17401408 | 0.74 | ENPP2 (0.80) | ENPP2 | |
| SCHEMBL5659043 | 0.74 | PPARA (0.52) | — | |
| SCHEMBL4861486 | 0.74 | PPARA (0.44) | CYP1A2FAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348334-B2 | Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-20030013729-A1 | New monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013729-A1 | New monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them | GPR119, FFAR1, FFAR3 | HTT 1033/4885CYP1A2 101/4885CYP2C9 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.